A study found that while the drug is effective in weight management throughout therapy, discontinuing use will result in the patient regaining weight
The combination group included those who added a newer generation GLP-1RA (i.e., exenatide once weekly [OW], dulaglutide, semaglutide OW T2D, or oral semaglutide) or dual GLP-1/GIP agonist (tirzepatide T2D) to their SGLT2i (i.e., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or bexagliflozin) treatment, with persistent use of a GLP-1RA and SGLT2i for 180 days each and an overlap 120 days, where the gap after exhaustion of days supply was required to be 30 days
For patients with recurrent issues accessing fresh medication before expiration, providers should explore barriers such as insurance coverage gaps, affordability concerns, or dosing frequency that may be contributing to medication waste
PAs ASAM has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1.50 CME credit for activities planned in accordance with AAPA CME Criteria
Connect with a licensed clinician, get a personalized semaglutide treatment plan, and stay on track with ongoing care
The main conditions that semaglutide is used to treat include type 2 diabetes and obesity